Back to results
US 10,500,178 B2Granted
LTB4 inhibition to prevent and treat human lymphedema
AssigneeThe Board of Trustees of the Leland Stanford Junior University
InventorsStanley G. Rockson, Mark R. Nicolls, Wen A. Tian, Xinguo Jiang, Jeanna Kim
Life of this patent
Estimating the term…
Abstract
Provided are therapeutic methods for treating a patient with lymphedema, or prophylactically treating an individual susceptible to lymphedema, by inhibiting synthesis activity of leukotriene B4.
Claims12
A method for the treatment of lymphedema in a human patient, the method comprising:
- administering to the patient (2S)-2-[[(2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl]amino]-4-methylpentanoic acid in an amount effective to prevent or reduce lymphedema symptoms restore architecture of lymphedematous tissue in acquired lymphedema.
A method for the treatment of lymphedema in a human patient, the method comprising:
- administering to the patient (2S)-2-[[(2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl]amino]-4-methylpentanoic acid at a dose of about 10-500 mg/day to restore architecture of lymphedematous tissue in acquired lymphedema.
Dependencies are inferred from the claim text.